Predictors of Survival in Sinonasal Adenocarcinoma

Abstract

Objectives To identify factors associated with disease-specific survival (DSS) in intestinal and nonintestinal sinonasal adenocarcinoma.

Design Retrospective review.

Setting Surveillance Epidemiology and End Results database.

Participants Adult patients with sinonasal adenocarcinoma.

Main Outcome Measures DSS.

Results We identified 325 patients; of these, 300 had the nonintestinal type and 25 had intestinal type histologies. The 5-year DSS rates for patients who had no treatment, radiation (RT), surgery, and surgery and postoperative RT were 42.5, 46.1, 85.6, and 72.6%, respectively (log-rank test; p < 0.001). Black race, age ≥ 75 years, paranasal sinus involvement, and high grade were independently associated with decreased DSS. Compared with RT, surgery (hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.15–0.77), and adjuvant RT (HR: 0.47; 95% CI, 0.26–0.86) were associated with improved DSS.

Conclusions There is no difference in prognosis between intestinal and nonintestinal subtypes of sinonasal adenocarcinoma. Treatment with surgery alone or adjuvant RT is associated with a more favorable prognosis.

Keywords

sinonasal - adenocarcinoma - intestinal type - nonintestinal type - survival

• References

• 1 Ganly I, Patel SG, Singh B , et al. Craniofacial resection for malignant paranasal sinus tumors: report of an International Collaborative Study. Head Neck 2005; 27 (7) 575-584
• 2 International Academy of Pathology, World Health Organization, International Agency for Research on Cancer. Pathology and Genetics of Head and Neck Tumours. Lyon, France: IARC Press; 2005
• 3 Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck 2012; 34 (6) 877-885
• 4 Haerle SK, Gullane PJ, Witterick IJ, Zweifel C, Gentili F. Sinonasal carcinomas: epidemiology, pathology, and management. Neurosurg Clin N Am 2013; 24 (1) 39-49
• 5 Luce D, Leclerc A, Bégin D , et al. Sinonasal cancer and occupational exposures: a pooled analysis of 12 case-control studies. Cancer Causes Control 2002; 13 (2) 147-157
• 6 Bhayani MK, Yilmaz TA, Sweeney A , et al. Sinonasal adenocarcinoma: a 16-year experience at a single institution. Head Neck 2014; . Available at: http://onlinelibrary.wiley.com/doi/10.1002/hed.23485/pdf . Accessed January 5, 2014
• 7 Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A. Prognostic factors in sinonasal tumors involving the anterior skull base. Head Neck 2004; 26 (2) 136-144
• 8 Heffner DK, Hyams VJ, Hauck KW, Lingeman C. Low-grade adenocarcinoma of the nasal cavity and paranasal sinuses. Cancer 1982; 50 (2) 312-322
• 9 Shah JP, Kraus DH, Bilsky MH, Gutin PH, Harrison LH, Strong EW. Craniofacial resection for malignant tumors involving the anterior skull base. Arch Otolaryngol Head Neck Surg 1997; 123 (12) 1312-1317
• 10 National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program brochure. Available at: http://seer.cancer.gov/about/factsheets/SEER_brochure.pdf . Accessed September 13, 2013
• 11 Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92 (12) 3012-3029
• 12 Lund VJ, Stammberger H, Nicolai P , et al; European Rhinologic Society Advisory Board on Endoscopic Techniques in the Management of Nose, Paranasal Sinus and Skull Base Tumours. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl 2010; (22) 1-143
• 13 Sanghvi S, Khan MN, Patel NR, Yeldandi S, Baredes S, Eloy JA. Epidemiology of sinonasal squamous cell carcinoma: a comprehensive analysis of 4994 patients. Laryngoscope 2014; 124 (1) 76-83
• 14 Ragin CC, Langevin SM, Marzouk M, Grandis J, Taioli E. Determinants of head and neck cancer survival by race. Head Neck 2011; 33 (8) 1092-1098
• 15 Harlan LC, Hankey BF. The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol 2003; 21 (12) 2232-2233
• 16 Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76 (11) 2343-2350
• 17 Trinkaus ME, Coleman A, D'Costa I, Sigston E, Rischin D. Recurrent intestinal type sinonasal adenocarcinoma treated with FOLFOX6 chemotherapy: case report and review of literature. Int J Case Rep Images 2012; 3 (8) 17-20
• 18 Licitra L, Suardi S, Bossi P , et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 2004; 22 (24) 4901-4906